Compare JVA & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JVA | HIND |
|---|---|---|
| Founded | 1971 | 2017 |
| Country | United States | United States |
| Employees | N/A | 18 |
| Industry | Packaged Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 15.2M |
| IPO Year | 1997 | 2016 |
| Metric | JVA | HIND |
|---|---|---|
| Price | $3.50 | $2.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 37.8K | 11.9K |
| Earning Date | 06-12-2026 | 05-20-2026 |
| Dividend Yield | ★ 1.71% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $90,655,294.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.48 | ★ N/A |
| Revenue Growth | ★ 17.54 | N/A |
| 52 Week Low | $2.93 | $1.75 |
| 52 Week High | $5.62 | $12.87 |
| Indicator | JVA | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 40.98 | 41.01 |
| Support Level | $3.28 | $2.02 |
| Resistance Level | $3.72 | $2.33 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 29.42 | 4.17 |
Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.